---
title: "CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) | OMER Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283003072.md"
description: "CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) | OMER Stock News"
datetime: "2026-04-16T04:45:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283003072.md)
  - [en](https://longbridge.com/en/news/283003072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283003072.md)
---

# CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) | OMER Stock News

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) | OMER Stock News

### Related Stocks

- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [There's A Lot To Like About OMER's (BIT:OMER) Upcoming €0.17 Dividend](https://longbridge.com/en/news/286365767.md)
- [Omeros Q1 net income turns positive after YARTEMLEA launch](https://longbridge.com/en/news/286310334.md)
- [Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?](https://longbridge.com/en/news/286962966.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)